For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro, ...

On Oct. 30, Lilly told investors to expect 2024 revenue to land in a range between $45.4 billion and $46 billion. Sales of the company's diabetes and weight loss treatments are soaring but not ...

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. According to the company ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

It said that may be at odds with the FDA's view. Insurers generally cover Lilly's and Novo's drugs for diabetes, but many do not cover the weight-loss medications. That has led many patients to ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $717.9 billion, has been making waves in the biopharmaceutical industry with its innovative treatments ...

Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow compounding pharmacies to continue churning out knockoffs to the popular diabetes and obesity drugs.